The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,958.00
Bid: 1,951.00
Ask: 1,953.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.103%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,958.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wednesday broker round-up UPDATE

Wed, 27th Nov 2013 09:14

Aviva: Nomura moves target price from 474p to 489p retaining a buy recommendation.Bellway: Numis upgrades to buy with a target price of 1690p.Breedon Aggregates: Jefferies starts with a target price of 42p and a buy recommendation.Britvic: UBS ups target price from 575p to 600p and keeps a neutral rating. Barclays upgrades to overweight with a target price of 690p.BTG: Deutsche Bank takes target price from 500p to 570p reiterating a buy recommendation. Panmure Gordon raises target price from 490p to 610p and retains a buy recommendation. Investec ups target price from 472p to 723p and maintains a buy recommendation.Compass Group: Numis increases target price from 850p to 900p and stays with its hold recommendation. Panmure Gordon takes target price from 820p to 900p maintaining a hold recommendation.De La Rue: Citi lowers target price from 1055p to 1000p downgrading from buy to neutral. Panmure Gordon ups target price from 786p to 806p and keeps a hold recommendation.Essar Energy: Deutsche Bank cuts target price from 175p to 75p, while maintaining a hold recommendation.Hargreaves Lansdown: Numis ups target price from 1006p to 1027p and maintains a hold recommendation.Hikma Pharmaceuticals: Goldman Sachs raises target price from 1180p to 1200p and keeps a neutral rating.IGas Energy: Canaccord Genuity shifts target price from 181p to 180p and stays with its buy recommendation.Imagination Technologies: Jefferies reduces target price from 628p to 393p, while leaving its buy recommendation unchanged.Immunodiagnostic Systems: Investec ups target price from 466p to 494p keeping a hold recommendation.Innovation Group: Panmure Gordon shifts target price from 41p to 44p and reiterates a buy recommendation.Jardine Lloyd Thompson Group: Westhouse Securities initiates with a target price of 1130p and an add rating.Marshalls: Jefferies initiates with a target price of 166p and a hold recommendation.Mitchells & Butlers: Nomura ups target price from 370p to 390p and keeps a neutral rating. JP Morgan upgrades from underweight to neutral with a target price of 400p. Panmure Gordon increases target price from 310p to 365p, but still recommends selling.MITIE Group: UBS moves target price from 305p to 320p, while downgrading from buy to neutral.Mondi: Goodbody cuts target price from 1290p to 1240p and reiterates a buy recommendation.NMC Health: Numis ups target price from 500p to 560p and reiterates a buy recommendation.Rio Tinto: Canaccord Genuity reduces target price from 4100p to 4000p, while its buy recommendation remains unchanged.Royal Mail: Investec places its target price (prev.: 544p) under review, while staying with its hold recommendation.Severn Trent: Goldman Sachs shifts target price from 2113p to 2110p, while leaving its buy recommendation unaltered.Shaftesbury: Liberum Capital takes target price from 622p to 636p and retains a hold recommendation.Smith (DS): Citi moves target price from 300p to 340p maintaining a buy recommendation. Goodbody ups target price from 285p to 295p, while downgrading to hold.Tesco: JP Morgan lowers target price from 335p to 315p and retains an underweight rating.Topps Tiles: Cantor Fitzgerald downgrades to sell with a target price of 82p.Tyman: Jefferies initiates with a target price of 269p and a buy recommendation.VP: Cantor Fitzgerald raises target price from 490p to 570p retaining a buy recommendation.
More News
3 Jan 2023 09:25

Hikma launches version of Xyrem medicine in US for treating narcolepsy

(Alliance News) - Hikma Pharmaceuticals PLC on Tuesday said it launched an authorised generic version of the Xyrem sodium oxybate prescription medicine in the US for treating narcolepsy.

Read more
3 Jan 2023 09:24

LONDON BROKER RATINGS: Citigroup cuts Wizz Air; Redburn likes CRH

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning, Monday and late Friday:

Read more
3 Jan 2023 09:03

LONDON MARKET OPEN: Stocks jump in first session of 2023

(Alliance News) - Stock prices in London made a strong start to the new year on Tuesday, despite weak Chinese data and the UK suffering a fresh wave of rail strikes.

Read more
3 Jan 2023 07:58

LONDON BRIEFING: Stocks called higher; China factory sector shrinks

(Alliance News) - Stocks in London are expected to start a new year on the front foot on Tuesday, after a mixed session in Asia amid weak Chinese economic data.

Read more
3 Jan 2023 07:46

Hikma launches generic narcolepsy solution in US

(Sharecast News) - Hikma Pharmaceuticals has launched an authorised generic version of Jazz Pharmaceuticals' 'Xyrem 1', or sodium oxybate oral solution, it announced on Tuesday.

Read more
8 Dec 2022 09:48

LONDON BROKER RATINGS: JPMorgan cuts Travis Perkins; BofA likes IAG

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
6 Dec 2022 10:48

RBC Capital Markets starts Hikma at 'outperform'

(Sharecast News) - RBC Capital Markets initiated coverage of Hikma Pharmaceuticals on Tuesday at 'outperform' with a 1,750p price target.

Read more
6 Dec 2022 10:26

LONDON BROKER RATINGS: JPMorgan cuts Lloyds but raises Barclays

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
15 Nov 2022 12:10

Credit Suisse initiates coverage of Hikma at 'outperform'

(Sharecast News) - Credit Suisse has initiated coverage of Hikma Pharmaceuticals with an 'outperform' rating.

Read more
15 Nov 2022 09:58

LONDON BROKER RATINGS: Jefferies cuts Aston Martin to 'underperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
14 Nov 2022 09:25

LONDON BROKER RATINGS: Credit Suisse cuts Ferrexpo to 'neutral'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
8 Nov 2022 09:39

LONDON BROKER RATINGS: Peel cuts Persimmon; Liberum raises Hammerson

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
3 Nov 2022 11:17

Hikma Pharmaceuticals reiterates 2022 guidance as costs widen

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reiterated annual guidance for all three of its businesses, continuing to expect them to underperform against 2021 due to rising costs.

Read more
3 Nov 2022 11:08

With tighter purse strings, is parity less probable for the pound?

STOXX 600 down 1.1%

*

Read more
3 Nov 2022 09:28

Banks, insurance dodge carnage as real estate stocks sink

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at .

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.